Dr. Reddy’s watch regulated markets for biosimilars

July 5, 2012 9:17 AM

Dr. Reddy’s Laboratories (DRL), was the first company to launch a monoclonal antibody biosimilar in India. The product itself was claimed to be a biosimilar of Mabthera but it is still not launched worldwide and the company is now planning to introduce new biosimilars in regulated markets. 

Dr. Reddy’s chairman K. Anji Reddy said that, the company made USD 26 million sales of biosimilars during fiscal 2011-12 and its revenues from biosimilar business have shown a CAGR of 39% from fiscal 2007-08.

“The biosimilars business continues along its impressive growth path. The company’s biosimilars business grew by 45% over last year and recorded sales of USD 26 million. These are helping to treat patients suffering from cancer and at prices that are significantly more affordable than the corresponding innovator drugs. Soon I expect to see Dr Reddy’s biosimilars entering developed markets,” Reddy said.

Currently, DRL has a portfolio of biosimilars like filgrastim, pegfilgrastim, rituximab and darbepoetin alfa that have a commercial presence in 13 emerging markets. According to Reddy, the company is waiting approvals for biosimilar filings in 20 new countries and was also seeing progress in pursuing regulated markets.

It was only last month that DRL entered into a partnership with German player Merck Serono, to co-develop a portfolio of biosimilar compounds in oncology, especially monoclonal antibodies. The deal includes development, manufacturing and commercialisation of the compounds globally, with some specific country exceptions.

“With 177 biosimilar and copy biologics, oncology is currently the largest target therapeutic area for development and marketing of biosimilars,”” Reddy told shareholders in the report.


Source: The Times of India

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!